These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 402691)

  • 41. C3 and C5-cleaving properdin enzymes formed on zymosan incubated with human serum: the decay and the regeneration of the enzymes.
    Fujita T; Takiuchi M; Matsumoto M; Nagaki K; Inai S
    Int Arch Allergy Appl Immunol; 1977; 53(4):303-9. PubMed ID: 67089
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Recruitment of properdin by bi-specific nanobodies activates the alternative pathway of complement.
    Pedersen DV; Rösner T; Hansen AG; Andersen KR; Thiel S; Andersen GR; Valerius T; Laursen NS
    Mol Immunol; 2020 Aug; 124():200-210. PubMed ID: 32599335
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Potentiation of antiboty-dependent cell-mediated cytotoxicity by target cell-bound C3b.
    Ghebrehiwet B; Medicus RG; Müller-Eberhard HJ
    J Immunol; 1979 Sep; 123(3):1285-8. PubMed ID: 469251
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A simple rosette assay for demonstration of complement receptor sites using complement-coated zymosan beads.
    Huber Ch; Wigzell H
    Eur J Immunol; 1976 Jun; 5(6):432-5. PubMed ID: 1086242
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Babesia rodhaini: requirement of complement for penetration of human erythrocytes.
    Chapman WE; Ward PA
    Science; 1977 Apr; 196(4285):67-70. PubMed ID: 841340
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cleavage of the third complement component (C3) and generation of the spasmogenic peptide, C3a, in human serum via the properdin pathway: demonstration of inhibitory as well as enhancing effects of epsilon-amino-caproic acid.
    Vogt W; Schmidt G; Lynen R; Dieminger L
    J Immunol; 1975 Feb; 114(2 Pt 1):671-7. PubMed ID: 804510
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The effects of complement activation by cobra venom factor on the migration of T and B lymphocytes into rat thoracic duct lymph.
    Spry CJ; Lane JT; Vyakarnam A
    Immunology; 1977 Jun; 32(6):947-54. PubMed ID: 301855
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Properdin binds to late apoptotic and necrotic cells independently of C3b and regulates alternative pathway complement activation.
    Xu W; Berger SP; Trouw LA; de Boer HC; Schlagwein N; Mutsaers C; Daha MR; van Kooten C
    J Immunol; 2008 Jun; 180(11):7613-21. PubMed ID: 18490764
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Complement and cell membranes.
    McConnell I; Lackhmann PJ
    Transplant Rev; 1976; 32():72-92. PubMed ID: 824770
    [No Abstract]   [Full Text] [Related]  

  • 50. The properdin pathway: mechanisms of complement activation and analogies to the classical pathway.
    Fearon DT; Austen KF; Ruddy S
    Rheumatology; 1975; 6():2-16. PubMed ID: 1105744
    [No Abstract]   [Full Text] [Related]  

  • 51. The interaction of glycoprotein C of herpes simplex virus types 1 and 2 with the alternative complement pathway.
    Hung SL; Peng C; Kostavasili I; Friedman HM; Lambris JD; Eisenberg RJ; Cohen GH
    Virology; 1994 Sep; 203(2):299-312. PubMed ID: 8053154
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Receptor for soluble C3 and C3b on human lymphoblastoid (RAJI) cells. Properties and biologocal significance.
    Theofilopoulos AN; Bokisch VA; Dixon FJ
    J Exp Med; 1974 Mar; 139(3):696-711. PubMed ID: 4591176
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A new activity of complement component C3: cell-bound C3b potentiates lysis of erythrocytes by C5b,6 and terminal components.
    Hammer CH; Abramovitz AS; Mayer MM
    J Immunol; 1976 Sep; 117(3):830-4. PubMed ID: 956655
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Binding of soluble immune complexes to Raji lymphocytes. Role of receptors for complement components, C1q and C3-C3b.
    Gupta RC; McDuffie FC; Tappeiner G; Jordon RE
    Immunology; 1978 Apr; 34(4):751-61. PubMed ID: 102587
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Complement activation by cigarette smoke.
    Robbins RA; Nelson KJ; Gossman GL; Koyama S; Rennard SI
    Am J Physiol; 1991 Apr; 260(4 Pt 1):L254-9. PubMed ID: 1902064
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Neutrophil extracellular traps can activate alternative complement pathways.
    Wang H; Wang C; Zhao MH; Chen M
    Clin Exp Immunol; 2015 Sep; 181(3):518-27. PubMed ID: 25963026
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In vitro effects of radiographic contrast media on the complement system.
    Hasselbacher P; Hahn J
    J Allergy Clin Immunol; 1980 Sep; 66(3):217-22. PubMed ID: 6251127
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Complement (C3) receptor-bearing lymphocyte-mediated cytotoxicity and lymphotoxin responses.
    O'Neill P; Mackler BF; Wyde P
    Cell Immunol; 1975 Nov; 20(1):33-41. PubMed ID: 1081909
    [No Abstract]   [Full Text] [Related]  

  • 59. Complement activation in semisolid media: insolubilization of alternative pathway convertases in agar gels with C3 nephritic factor-containing sera.
    Arnaout MA; Davis AE; Rosen RS; Alper CA
    J Immunol; 1977 Oct; 119(4):1316-20. PubMed ID: 894039
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Complement activation in semi-solid medium: Insolubilization of properdin and the third component of complement (C3) in agar gels.
    Ziegler JB; Watson L; Goodkofsky I; Alper CA; Lepow IH
    J Immunol; 1976 Jan; 116(1):75-9. PubMed ID: 812917
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.